Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Clinical trial NCT05267106 · TERMINATED
Trial details
- NCT number
- NCT05267106
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-20
- Primary completion
- 2024-12-17
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.